Lipella Pharmaceuticals announced the expansion of its Scientific Advisory Board to include oncology expertise. The new committee members are: Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the William Beaumont School of Medicine; and Pradeep Tyagi, PhD, MBA, Professor of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA. Drs. Hafron and Tyagi have complementing expertise in both clinical and translational research in cancer treatment, with a focus on urologic oncology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
- Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
- Lipella Pharmaceuticals initiated with a Buy at Maxim
- Lipella Pharmaceuticals to publish abstract on preclinical support for LP-50
- Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
- Lipella Pharmaceuticals announces FDA Type C meeting for LP-10